SCHEMBL4834855

SCHEMBL4834855

Cc1c(Cl)cnc2[nH]c(-c3ccc(O)c([N+](=O)[O-])c3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
MAPT P10636 4/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPBWR1 P48145 2/20 0.38
ADORA1 P30542 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
APOBEC3G Q9HC16 1/20 0.38
XDH P47989 1/20 0.37
ABCC1 P33527 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
DHFR P00374 1/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
ALOX12 P18054 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834982 0.91 MAPT (0.39) MAPTNPC1RAB9ANPBWR1ADORA1
SCHEMBL4837512 0.87 NPBWR1 (0.38) MAPTNPC1RAB9ANPBWR1ADORA1
SCHEMBL4846517 0.78 GAA (0.39) MAPTNPC1RAB9AALDH1A1KDM4E
SCHEMBL4841712 0.75 KDM4E (0.47) MAPTNPC1RAB9AADORA1ALDH1A1
SCHEMBL4845766 0.69 MAPT (0.46) MAPTNPC1RAB9ANPBWR1ALDH1A1
SCHEMBL4843765 0.68 TNKS (0.50) MAPTNPC1RAB9ANPBWR1ALDH1A1
SCHEMBL11862089 0.68 GRK6 (0.53) GRK6PDE3BPDE3AMAPTALDH1A1
SCHEMBL32670749 0.67 MGAM (0.49) GRK6MAPTALDH1A1ABCG2GAA
SCHEMBL4840653 0.67 CHEK1 (0.38) MAPK1
SCHEMBL7397857 0.67 MMP2 (0.63) MAPTNPC1RAB9ANPBWR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
CN-100358893-C Certain novel imidazopyridines and uses thereof ASTRAZENECA AB (SE) 2008-01-02 CN disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
CN-1684964-A Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2005-10-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 GRK6 77/4885PDE3B 632/4885PDE3A 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.